| Autor: |
Elbezanti WO; Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA.; Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA., Challagundla KB; Department of Biochemistry and Molecular Biology, The Fred and Pamela Buffett Cancer Center, The Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA., Jonnalagadda SC; Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA., Budak-Alpdogan T; Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA., Pandey MK; Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA. |
| Abstrakt: |
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments. |
